Drug Information

Drug General Information
Drug ID
D0M0PY
Former ID
DPR000039
Drug Name
DX-890
Indication Acute lung injury; Acute respiratory distress syndrome; Cystic fibrosis [ICD9: 277.0, 518.5, 518.82, 709.2; ICD10:E84, J80, L90.5] Phase 2 [522003]
Company
Dyax Corp.
CAS Number
CAS 10024-97-2
ChEBI ID
ChEBI:17045
SuperDrug ATC ID
N01AX13
SuperDrug CAS ID
cas=010024972
Target and Pathway
Target(s) Leukocyte elastase Target Info Inhibitor [536500]
KEGG Pathway Transcriptional misregulation in cancer
Systemic lupus erythematosus
Pathway Interaction Database Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
C-MYB transcription factor network
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
WikiPathways Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Human Complement System
Degradation of collagen
References
Ref 522003ClinicalTrials.gov (NCT00455767) Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients. U.S. National Institutes of Health.
Ref 536500Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.